Our findings reveal a correlation between increased CEBPB expression and unfavorable clinical outcomes, such as reduced survival rates, suggesting that CEBPB could be a potential prognostic biomarker for ccRCC. Here, CEBPB is linked to nonpapillary renal cell carcinoma.